Armis Biopharma, a privately held biopharmaceutical company based in Fort Collins, CO, has announced the appointment of Michael J. Voss as the new CEO, succeeding Ted Ziemann who is retiring on July 1st. Ziemann, who has served as CEO for six years, will continue to hold the position of Chairman on the Board of Directors. Voss joined Armis Biopharma in January 2024 as Chief Commercial Officer, bringing an extensive background in commercial operations from companies like Safen Medical, Acelity, Cordis Cardiology (Johnson & Johnson), and Boston Scientific. The company, known for its Veriox platform technology, has developed various products for surface disinfection, wound care, and decontaminating chemical and biological warfare agents. Recent successes include securing a $20.3 million contract with the Defense Threat Reduction Agency and a $2.1 million grant from the National Institute of Health for the development of Veriox DECON products. Armis Biopharma aims to fully commercialize its growing list of regulatory-cleared products under Voss’s leadership.
Biopharmaceutical, Medical Devices, Defense,United States
https://mergersacquisitions.einnews.com/pr_news/724388756/armis-biopharma-names-michael-j-voss-as-new-ceo-replacing-ted-ziemann-who-is-retiring?ref=rss&ecode=Q1vNcweEggLWKz7L&utm_source=RSSNews&utm_medium=rss&utm_campaign=Mergers+%26+Acquisitions+News&utm_content=article